EXSCIENTIA
8.7.2021 10:02:52 CEST | Business Wire | Press release
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro , also known as 3CLpro , the causative agent of COVID-19. Mpro is essential for the replication of coronavirus, so administering an Mpro inhibitor to patients as a standalone antiviral or alongside other concurrent treatments could provide a useful frontline therapy.
Exscientia’s AI-based platform will be used to optimise the novel small molecule inhibitors into a therapeutic development candidate, designed to be active against SARS-CoV-2 and other coronaviruses. The project’s goal is to identify potential pan-coronavirus therapeutics that could be effective against COVID-19, and also new mutations or other SARS viruses that may emerge.
The new grant provided by the COVID-19 Therapeutics Accelerator - an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed up the response to the pandemic - comes in addition to recent backing from the Gates Foundation supporting Exscientia’s work in developing treatments for tuberculosis, malaria and non-hormonal contraceptives which began in January 2021. Under the new grant, Exscientia will receive $1.5 million which will be used to advance a development candidate on achieving defined milestones. The virus protease inhibitors will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimised compounds, fulfilling complex design goals faster and more effectively than with conventional drug discovery methods.
Dr. Denise Barrault, Senior Portfolio Manager at Exscientia, commented, “The danger of new emerging strains and mutations of coronavirus means there is an urgent need for new antiviral drugs in this pandemic alongside vaccines, to respond more quickly in potential future coronavirus pandemics. We believe that the world needs innovation to accelerate the discovery of more effective counter-measures for a range of infectious diseases, including COVID-19.”
Exscientia has built a track record of improving and accelerating drug discovery by advancing the first three completely AI-designed small molecule drug candidates into clinical trials. In addition to its own proprietary programmes, Exscientia has entered into collaborations with major pharmaceutical companies including Bristol Myers Squibb, Bayer, Sanofi and Dainippon Sumitomo, as well as multiple biotech companies. The company currently has more than 20 partners or wholly owned programmes for diseases involving cancer, immunology, the central nervous system, and genetic mutations.
ENDS
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005344/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Goes for Gold in Global Manufacturing Standards4.3.2026 14:11:00 CET | Press release
Quality, Certified: Mary Kay Achieves ISO 22716 Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, has achieved ISO 22716 certification, the internationally recognized gold standard for cosmetic Good Manufacturing Practices (GMP), reinforcing the company’s unwavering commitment to product quality, safety, and consumer trust worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304100367/en/ Chaun Harper, Chief Supply Chain Officer at Mary Kay Inc., emphasized the broader significance of the milestone: “At Mary Kay, quality is not a checkbox – it is a promise, an operational framework, and a culture. (Photo Credit: Mary Kay Inc.) Key Data Points About Mary Kay’s Global Manufacturing: Built on 26 acres of land, Mary Kay’s state-of-the-art, Silver LEED-certified Richard R. Rogers Manufacturing and R&D Center (R3) is located in Lewisville, Texas. R3 is a $100+ million investment and is a 453,00
NelsonHall Recognizes LTM as a Leader in GenAI & Process Automation for Banking4.3.2026 13:45:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in the ‘Overall’ market segment in the NelsonHall NEAT Evaluation for GenAI & Process Automation in Banking 2025. In the NEAT framework, Leaders are vendors that demonstrate high capability relative to peers in delivering immediate client benefit while also meeting future client requirements. The recognition positions LTM among the top-performing vendors evaluated for their ability to deliver both immediate business impact and long-term innovation capability in GenAI and process automation services for the banking sector. The evaluation highlights LTM’s depth of experience in financial services, which accounts for a large portion of its overall revenues, and its focused investments in GenAI, agentic AI, and process automation capabilities delivered through its BlueVerse™ platform. LTM has digital agents dedicated to manage GenAI and process automation services, supporting banking cl
Americhem Expands Aircraft Interior Portfolio with PFAS-Free Thermoplastic Platform Meeting 55/55 OSU, Low Smoke, and Low Toxicity Requirements4.3.2026 13:00:00 CET | Press release
Americhem is expanding its aircraft interior materials portfolio with ColorFast® SFT5500, a PFAS-free high-performance thermoplastic engineered to meet FAA 14 CFR 25.853, Appendix F, Part IV, 55/55 OSU heat release requirements while delivering low smoke and low toxicity characteristics for aircraft interior applications. PFAS-free thermoplastic systems capable of achieving 55/55 OSU performance while maintaining low smoke and low toxicity characteristics remain limited in the aerospace market. ColorFast® SFT5500 addresses this need with demonstrated 55/55 OSU heat release performance, low smoke emission characteristics, and low flaming-mode toxicity performance in a high-performance thermoplastic platform designed specifically for injection-molded interior components. Aircraft interior thermoplastics must meet stringent fire standards while maintaining durability, thermal stability, and process consistency. As legacy fluorinated material systems face increasing regulatory scrutiny, ma
NETSCOUT Reveals Qualitative Shifts in DDoS Attack Sophistication, Infrastructure Capacity, and Threat Actor Capabilities4.3.2026 12:05:00 CET | Press release
AI Adoption, coordinated botnets, and persistent hacktivists groups drove millions of attacks NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT), today released its second half of the year 2025 Distributed Denial-of-Service (DDoS) Threat Intelligence Report, revealing sophisticated attacker collaboration, resilient botnets, and compromised IoT infrastructure that drove more than eight million DDoS attacks worldwide – some as large as 30 terabits per second (Tbps) – marking a new era of hyper-scale, coordinated threat activity that continues to outpace global takedown efforts. Meanwhile, the accelerating growth of DDoS-for-hire services is empowering a broader range of threat actors, intensifying operational risk to digitally connected organizations and enterprises. Implications for security professionals extend far beyond volumetric concerns and include reconnaissance and adaptive evasion which challenge traditional defense paradigms. Organizations must match adversarial innovation with intelligen
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally4.3.2026 12:00:00 CET | Press release
Expansion Signals Acceleration in AI, Clinical Innovation, and International Growth WHOOP, the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the company continues to scale globally. The hiring expansion reflects a clear strategic priority: bolstering a team that will define the future of human performance and health technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304866977/en/ WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally “Right now, companies are debating whether to hire more people or just invest in AI,” said Will Ahmed, Founder and CEO of WHOOP. “We are doing both. We are doubling down on exceptional talent and doubling down on world-class AI tools because the combination is what wins. Health monitoring is becoming one of the most important p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom